NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal Reserve's upcoming policy meeting. As per CME Group's FedWatch tool, as of Tuesday, market expectations for a March rate hike are 94.4 percent. The Dow Jones Industrial Average increased 0.47 percent to close at 24,727.27, while the S&P 500 Index gained 0.15 percent to close at 2,716.94. The Nasdaq Composite Index climbed 0.27 percent to close at 7,364.30.
"We've seen volatility come back into markets. Stocks have become more of a two-sided trade. Markets do seem more comfortable at these levels, but it'll probably take a month or two before things settle. We want to see more clarity with what's actually going on with trade, with underlying economic data. Those things will cause the market to break out one way or the other," said Shawn Cruz, senior markets specialist at TD Ameritrade.
RDI Initiates Coverage on:
Loxo Oncology, Inc.
AnaptysBio's stock moved 3.94% higher Tuesday, to close the day at $113.73. The stock recorded a trading volume of 244,444 shares, which was below its three months average volume of 295,315 shares. In the last year, AnaptysBio's shares have traded in a range of 18.15 - 134.00. The share price has gained 526.61% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $115.22 is greater than its 200-day moving average of $83.01. Shares of AnaptysBio have fallen roughly 6.03 percent in the past month and are up 12.92 percent year-to-date.
Access RDI's AnaptysBio, Inc. Research Report at:
On Tuesday, shares of Loxo Oncology recorded a trading volume of 436,665 shares, which was above the three months average volume of 381,931 shares. The stock ended the day 3.00% higher at 121.95. The share price has gained 200.96% from its 52-week low with a 52-week trading range of 40.52 - 135.74. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $112.11 is greater than its 200-day moving average of $92.16. Shares of Loxo Oncology have gained roughly 16.89 percent in the past month and are up 44.87 percent year-to-date.
Access RDI's Loxo Oncology, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute